Lv2
142 积分 2023-06-24 加入
Role of pharmacologically active metabolites in drug discovery and development
2天前
已完结
Projection of Exposure and Efficacious Dose Prior to First-in-Human Studies: How Successful Have We Been?
2天前
已完结
Comparison of Hematological Toxicity of mFOLFOX6 vs CAPOX Chemotherapy Regimens in Adjuvant Treatment of Stage II-III Colon Cancer Patients
4天前
已完结
Dose translation between laboratory animals and human in preclinical and clinical phases of drug development
13天前
已完结
Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor
1个月前
已完结
Discovery and development of MRTX1133, a potent, selective, noncovalent inhibitor of KRASG12D
1个月前
已完结
Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck
2个月前
已完结
ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)
2个月前
已完结
Use of Structural Alerts for Reactive Metabolites in the Application SpotRM
2个月前
已完结
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury
2个月前
已完结
皖公网安备34019202002308
